Category Archives: Business and Investments

Latest From Business and Investments

Spotlight on China

Cho

The 20th annual BIO International Convention is wrapping up in Chicago. Experts and leaders from leading global biotechnology, biologics and investment companies gathered together to discuss the opportunities and challenges in the biologics industry. A large China Food and Drug Administration (CFDA) delegation led by Deputy Commissioner Bian Zhenjia participated in a half-day session dedicated to developing a world-class therapeutic biologics industry in China. There has been a shift in recent years in the usage Read More >

Business and Investments  |  1 Comment  |  Email This Post
Tags: , , , ,

State of the Biotech Industry: Burrill’s Biotech 2013 Report

Burrill

To open his Super Session at the 2013 BIO International Convention, G. Steven Burrill, CEO of Burrill & Company, injected some humor for the hundreds of attendees in the audience, saying after 45 years in the biotech industry, 27 years authoring the Burrill State-of-the-Industry Report and 20 years of presenting the report at Convention, he was determined to get through 228 slides in 90 minutes. And, he delivered, providing a comprehensive snapshot of the industry Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Protect Yourself from a Hack Attack

Protect Yourself from a Hack Attack

Gone are the days when biotech’s biggest activist threats came from lab break-ins and physical attacks. Today almost anyone wishing to damage companies can steal, disrupt or harm employees 24-hours a day and from anywhere in the world. Hackers are anything BUT anonymous Last year the notorious group Anonymous took credit for hacking Monsanto Co. due to the company’s alleged “crimes against humanity.” It was the third hack Anonymous aimed against the the company, and Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Ernst & Young’s Beyond Borders: Matters of Evidence

Super Session

Hundreds of attendees turned out to glean insights from findings outlined in Ernst & Young LLP’s (EY) 27th annual report on the biotechnology industry – Beyond borders: matters of evidence – officially launched at Tuesday morning’s Super Session at the 2013 BIO International Convention. The report was presented by Glen Giovannetti and Gautam Jaggi of EY’s Global Life Sciences Center, and the Super Session featured a panel of industry leaders, including: Brian Edelman, VP, Corporate Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Results from the BIO Convention 2013 Meeting Analysis of Therapeutic In/Out Licensors

BIO’s results from the BIO 2013 Convention 1×1 meeting analysis conducted to identify trends and intentions of therapeutic in-licensors and out-licensors were released today. The analysis looked at the meeting activity of 180 in-licensors attending the Chicago conference in terms of what therapeutic areas and stages of development were in highest demand. Of the 804 drug R&D companies, companies in Phase I/Rare Disease came out ahead as a group, with an average of >17 meetings/company. This was followed by Phase Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,